TIRZEPATIDE, A DUAL GIP AND GLP-1 RECEPTOR AGONIST, IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS: EFFICACY AND SAFETY
DOI:
https://doi.org/10.47820/recima21.v5i4.5133Keywords:
Diabetes mellitus. Obesity, Treatment.Abstract
Introduction: Type 2 diabetes mellitus (DM2) is a chronic condition characterized by insulin resistance and deficiency in insulin production by the pancreas. Treatment of type 2 diabetes mellitus is generally individualized and aims to effectively control blood glucose levels, minimize complications and improve patients' quality of life. Tirzepatide is a bifunctional GLP-1 and glucagon receptor agonist with the potential to revolutionize the treatment of type 2 diabetes mellitus. Objectives: To provide a comprehensive overview of the role of tirzepatide in the current therapeutic arsenal of type 2 diabetes mellitus, focusing on its efficacy and security. Materials and methods: This is an integrative review, in which the guiding question was “Is tirzepatide safe and effective in the treatment of type 2 diabetes mellitus?”. The search for articles took place in the main databases (PubMed and Scielo) using the terms "tirzepatide", "treatment" and "type 2 diabetes" combined using Boolean operators. Results and discussion: Tirzepatide is the first dual receptor agonist that was recently approved for the treatment of T2DM by the Food Drug Administration (FDA). The efficacy in reducing blood glucose and body weight is stronger than that of GLP-1, while the safety profile and incidence of adverse events appear comparable. Conclusion: Tirzepatide is a new incretin-based therapy for T2DM, it has shown robust reductions in HbA1c and body weight, without an increased risk of hypoglycemia.
Downloads
References
ARTASENSI, Angelica et al. Type 2 diabetes mellitus: a review of multi-target drugs. Molecules, v. 25, n. 8, p. 1987, 2020. DOI: https://doi.org/10.3390/molecules25081987
BARBOSA, Franky Marleo Carvalho; DA SILVA BARBOSA, Elma; ANDRETO, Vanessa Ribeiro. Diabetes Melittus: fatores históricos acerca do surgimento e tratamento. Brazilian Journal of Health Review, v. 6, n. 6, p. 32905-32929, 2023. DOI: https://doi.org/10.34119/bjhrv6n6-489
BHAGAVATHULA, Akshaya Srikanth; VIDYASAGAR, Kota; TESFAYE, Wubshet. Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized phase II/III trials. Pharmaceuticals, v. 14, n. 10, p. 991, 2021. DOI: https://doi.org/10.3390/ph14100991
DE BLOCK, Christophe et al. Tirzepatide for the treatment of adults with type 2 diabetes: an endocrine perspective. Diabetes, Obesity and Metabolism, v. 25, n. 1, p. 3-17, 2023. DOI: https://doi.org/10.1111/dom.14831
DE SOUSA, Luís Manuel Mota et al. A metodologia de revisão integrativa da literatura em enfermagem. Revista investigação em enfermagem, v. 21, n. 2, p. 17-26, 2017.
DOS SANTOS, Vitor Cardoso et al. Diabetes Mellitus Tipo 2-aspectos epidemiológicos, fisiopatológicos e manejo terapêutico. Brazilian Journal of Development, v. 9, n. 3, p. 9737-9749, 2023. DOI: https://doi.org/10.34117/bjdv9n3-058
DUTTA, Deep et al. Efficacy and safety of novel twincretin tirzepatide a dual GIP and GLP-1 receptor agonist in the management of type-2 diabetes: A Cochrane meta-analysis. Indian Journal of Endocrinology and Metabolism, v. 25, n. 6, p. 475-489, 2021. DOI: https://doi.org/10.4103/ijem.ijem_423_21
ERCOLE, Flávia Falci; MELO, Laís Samara de; ALCOFORADO, Carla Lúcia Goulart Constant. Revisão integrativa versus revisão sistemática. Reme: Revista Mineira de Enfermagem, v. 18, n. 1, p. 09-11, 2014. DOI: https://doi.org/10.5935/1415-2762.20140001
FRIAS, Juan Pablo et al. Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: a 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens. Diabetes, Obesity and Metabolism, v. 22, n. 6, p. 938-946, 2020. DOI: https://doi.org/10.1111/dom.13979
GALLWITZ, Baptist. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology, v. 13, p. 1004044, 2022. DOI: https://doi.org/10.3389/fendo.2022.1004044
KANEKO, Shizuka. Tirzepatide: a novel, once-weekly dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes. TouchREVIEWS in Endocrinology, v. 18, n. 1, p. 10, 2022. DOI: https://doi.org/10.17925/EE.2022.18.1.10
KARAGIANNIS, Thomas et al. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia, v. 65, n. 8, p. 1251-1261, 2022. DOI: https://doi.org/10.1007/s00125-022-05715-4
KUSHNER, Pamela et al. Efficacy and safety of tirzepatide in adults with type 2 diabetes: a perspective for primary care providers. Clinical Diabetes, v. 41, n. 2, p. 258-272, 2023. DOI: https://doi.org/10.2337/cd22-0029
LEE, Clare J. et al. Tirzepatide as monotherapy improved markers of beta-cell function and insulin sensitivity in type 2 diabetes (SURPASS-1). Journal of the Endocrine Society, v. 7, n. 5, p. bvad056, 2023. DOI: https://doi.org/10.1210/jendso/bvad056
LEMPESIS, Ioannis G.; LIU, Junli; DALAMAGA, Maria. The catcher in the gut: Tirzepatide, a dual incretin analog for the treatment of type 2 diabetes mellitus and obesity. Metabolism open, v. 16, p. 100220, 2022. DOI: https://doi.org/10.1016/j.metop.2022.100220
MENDES, Karina Dal Sasso; SILVEIRA, Renata Cristina de Campos Pereira; GALVÃO, Cristina Maria. Revisão integrativa: método de pesquisa para a incorporação de evidências na saúde e na enfermagem. Texto & contexto-enfermagem, v. 17, p. 758-764, 2008. DOI: https://doi.org/10.1590/S0104-07072008000400018
NAUCK, Michael A.; D ‘ALESSIO, David A. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovascular diabetology, v. 21, n. 1, p. 169, 2022. DOI: https://doi.org/10.1186/s12933-022-01604-7
PALAK, Dutta et al. Tirzepatide: A Promising Drug for Type 2 Diabetes and Beyond. Cureus, v. 15, n. 5, 2023. DOI: https://doi.org/10.7759/cureus.38379
RAZZAKI, Tanzila S.; WEINER, Alyson; SHUKLA, Alpana P. Tirzepatide: does the evidence to date show potential for the treatment of early stage type 2 diabetes?. Therapeutics and Clinical Risk Management, p. 955-964, 2022. DOI: https://doi.org/10.2147/TCRM.S328056
SHI, Qingyang et al. Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ, v. 381, 2023.
SINHA, Rachel et al. Efficacy and safety of tirzepatide in type 2 diabetes and obesity management. Journal of Obesity & Metabolic Syndrome, v. 32, n. 1, p. 25, 2023. DOI: https://doi.org/10.7570/jomes22067
TANG, Yan et al. Efficacy and safety of tirzepatide in patients with type 2 diabetes: A systematic review and meta-analysis. Frontiers in Pharmacology, v. 13, p. 1016639, 2022. DOI: https://doi.org/10.3389/fphar.2022.1016639
THOMAS, Melissa K. et al. Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes. The Journal of Clinical Endocrinology & Metabolism, v. 106, n. 2, p. 388-396, 2021. DOI: https://doi.org/10.1210/clinem/dgaa863
ZHOU, Qian et al. Efficacy and safety of tirzepatide, dual GLP-1/GIP receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetology & Metabolic Syndrome, v. 15, n. 1, p. 222, 2023. DOI: https://doi.org/10.1186/s13098-023-01198-4
Downloads
Published
How to Cite
License
Copyright (c) 2024 RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218
This work is licensed under a Creative Commons Attribution 4.0 International License.
Os direitos autorais dos artigos/resenhas/TCCs publicados pertecem à revista RECIMA21, e seguem o padrão Creative Commons (CC BY 4.0), permitindo a cópia ou reprodução, desde que cite a fonte e respeite os direitos dos autores e contenham menção aos mesmos nos créditos. Toda e qualquer obra publicada na revista, seu conteúdo é de responsabilidade dos autores, cabendo a RECIMA21 apenas ser o veículo de divulgação, seguindo os padrões nacionais e internacionais de publicação.
